Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-84f7be3473056391e7ee18f2463847a8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-84f7be3473056391e7ee18f2463847a8"/>
<resource>
<Composition>
<id value="composition-en-84f7be3473056391e7ee18f2463847a8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-84f7be3473056391e7ee18f2463847a8"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-84f7be3473056391e7ee18f2463847a8</b></p><a name="composition-en-84f7be3473056391e7ee18f2463847a8"> </a><a name="hccomposition-en-84f7be3473056391e7ee18f2463847a8"> </a><a name="composition-en-84f7be3473056391e7ee18f2463847a8-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1254/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - jorveza</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/17/1254/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp84f7be3473056391e7ee18f2463847a8"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - jorveza"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Jorveza is and what it is used for</li><li>What you need to know before you take Jorveza</li><li>How to take Jorveza</li><li>Possible side effects</li><li>How to store Jorveza</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What jorveza is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What jorveza is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Jorveza contains the active substance budesonide, a corticosteroid medicine that reduces inflammation.</p><p>It is used in adults (older than 18 years of age) to treat eosinophilic oesophagitis, which is an inflammatory condition of the gullet (food pipe) that causes problems with swallowing food.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take jorveza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take jorveza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Jorveza</p><p>if you are allergic to budesonide or any of the other ingredients of this medicine (listed in section 6).</p><p>Warnings and precautions<br/>Talk to your doctor or pharmacist before taking Jorveza if you have:</p><p>tuberculosis</p><p>high blood pressure</p><p>diabetes, or if somebody in your family has diabetes</p><p>weakening of the bones (osteoporosis)</p><p>ulcers in the stomach or first part of the small intestine (peptic ulcer)</p><p>increased pressure in your eye (which can cause glaucoma) or eye problems such as clouding of the lens (cataracts) or if somebody in your family has glaucoma</p><p>liver disease.</p><p>If you have any of the conditions mentioned above you may be at increased risk of side effects. Your doctor will decide on the appropriate measures and if it is still all right for you to take this medicine.</p><p>If you develop swelling of your face, particularly around your mouth (lips, tongue or throat) and/or difficulties to breathe or swallow, stop taking Jorveza and contact your doctor immediately. These may be signs of an allergic reaction, which may also include rash and itching (see also section 4).</p><p>Jorveza may cause typical side effects of corticosteroid medicines and may affect all parts of the body, particularly when you take this medicine at high doses and over a long time (see section 4).</p><p>Further precautions during treatment with Jorveza</p><p>Contact your doctor if you get blurred vision or have other problems with your vision.</p><p>Take the following precautions during treatment with Jorveza because your immune system may be weakened:</p><p>Tell your doctor if you get fungal infections in the mouth, throat and gullet or if you think you have any infection during treatment with this medicine. Symptoms of fungal infection can be white spots in the mouth and throat and difficulty in swallowing. The symptoms of some infections can be unusual or less noticeable.</p><p>Keep away from people who have chickenpox or herpes zoster (shingles) if you have not had these infections. The effects of these illnesses can be much more severe during treatment with this medicine. If you do come into contact with chickenpox or shingles, see your doctor straight away. Please also report your vaccination status to your doctor.</p><p>Tell your doctor if you have not yet had measles and/or if and when you have received your last vaccination for this disease.</p><p>If you need to be vaccinated please speak to your doctor first.</p><p>If you know that you are due to have an operation please tell your doctor that you are taking Jorveza.</p><p>Jorveza could affect the results of adrenal function tests (ACTH stimulation test) ordered by your doctor or in hospital. Tell your doctors that you are taking Jorveza before you have any tests.</p><p>Children and adolescents Jorveza should not be used in children and adolescents under 18 years of age. The use of this medicine in children younger than 18 years of age has not yet been studied.</p><p>Other medicines and Jorveza Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some of these medicines may increase the effects of Jorveza and your doctor may wish to monitor you carefully if you are taking these medicines.<br/>In particular:</p><p>ketoconazole or itraconazole (to treat fungal infections)</p><p>clarithromycin, an antibiotic medicine used to treat infections</p><p>ritonavir and cobicistat (to treat HIV infections)</p><p>oestrogens (used for hormone replacement therapy or contraception)</p><p>cardiac glycosides such as digoxin (medicines used to treat heart conditions)</p><p>diuretics (to remove excess fluid from the body).</p><p>Jorveza with food and drink You should not drink grapefruit juice whilst you are taking this medicine as this can worsen its side effects.</p><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Do not take this medicine during pregnancy without checking with your doctor first.</p><p>Do not take this medicine if you are breast-feeding unless you have checked with your doctor. Budesonide passes in small amounts into the breast milk. Your doctor will help you decide whether you should continue treatment and not breast-feed or if you should stop treatment over the period your baby is being breast-fed.</p><p>Driving and using machines Jorveza is not expected to affect your ability to drive or use machines.</p><p>Jorveza contains sodium This medicine contains 52 mg sodium (main component of cooking/table salt) per daily dose. This is equivalent to 2.6% of the recommended maximum daily dietary intake of sodium for an adult.</p></div>
</text>
</section>
<section>
<title value="3. How to take jorveza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take jorveza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose for treatment of acute episodes is two 1 mg orodispersible tablets (2 mg budesonide) per day. Take one 1 mg orodispersible tablet in the morning and one 1 mg orodispersible tablet in the evening.</p><p>The recommended dose for prevention of further episodes is two 0.5 mg orodispersible tablets (1 mg budesonide) per day or two 1 mg orodispersible tablets (2 mg budesonide) per day, depending on your body s response to the treatment. Take one orodispersible tablet in the morning and one orodispersible tablet in the evening.</p><p>Method of administration Take the orodispersible tablet immediately once removed from the blister package.</p><p>Take the orodispersible tablet after a meal.</p><p>Place the orodispersible tablet on the tip of your tongue and close your mouth. Press it gently against the roof of your mouth with your tongue until it has disintegrated completely (this usually takes at least two minutes but may take up to 20 minutes). Swallow the disintegrated material with saliva little by little, as the orodispersible tablet breaks up. Do NOT take any liquid with the orodispersible tablet.</p><p>Do not chew or swallow the undisintegrated orodispersible tablet.</p><p>Do not eat, drink, brush your teeth or rinse your mouth for at least 30 minutes after you have taken the orodispersible tablet. Do not use any oral solutions, sprays or chewable tablets for at least 30 minutes before or after administration of the orodispersible tablet. This will ensure that your medicine works properly.</p><p>Kidney and liver problems<br/>If you have any problem with your kidney or liver, talk to your doctor. If you have a kidney problem, your doctor will decide if Jorveza is suitable for you. In case your kidney problems are severe, you should not take Jorveza. If you have any liver disease, you should not take Jorveza.</p><p>Duration of treatment Initially, your treatment should last about 6 to 12 weeks.<br/>After treatment of the acute episode, your doctor will decide how long and with which dose you are to continue the treatment, depending on your condition and your response to the treatment.</p><p>If you take more Jorveza than you should If you have taken more orodispersible tablets than you should, take your next dose as prescribed. Do not take a smaller amount. Ask your doctor or pharmacist if you are in doubt. Take the carton and this leaflet with you if possible.</p><p>If you forget to take Jorveza If you miss a dose, just take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Jorveza Speak to your doctor if you want to interrupt or end your treatment early. It is important that you do not stop taking your medicine without talking to your doctor. Keep taking your medicine until your doctor tells you to stop, even if you feel better.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Stop using Jorveza and seek medical attention immediately if you notice any of the following symptoms:</p><p>swelling of the face, particularly of the eyelids, lips, tongue or throat (angioedema) which may be symptoms of an allergic reaction.</p><p>The following side effects have been reported during the use of Jorveza:</p><p>Very common: may affect more than 1 in 10 people</p><p>fungal infections in the gullet (which can cause pain or discomfort when swallowing)</p><p>fungal infections in the mouth and throat (symptoms can be white spots)</p><p>Common: may affect up to 1 in 10 people</p><p>headache</p><p>heartburn</p><p>indigestion</p><p>feeling sick (nausea)</p><p>tingling or numbness in your mouth, dry mouth</p><p>taste disorder, burning tongue</p><p>upper abdominal (belly) pain</p><p>tiredness</p><p>decreased amount of the hormone cortisol in your blood</p><p>dry eyes.</p><p>difficulty in sleeping</p><p>problems with tongue</p><p>cold sore (oral herpes)</p><p>Uncommon: may affect up to 1 in 100 people</p><p>anxiety, agitation</p><p>dizziness</p><p>high blood pressure</p><p>cough, dry throat, sore throat, common cold</p><p>abdominal (belly) pain, abdominal distension (bloating)</p><p>difficulty swallowing</p><p>inflammation of the stomach, ulcers in the stomach</p><p>swelling of the lips</p><p>rash, itching rash</p><p>sensation of foreign body</p><p>pain in the mouth or throat</p><p>painful gums,</p><p>decreased level of osteocalcin, weight gain.</p><p>The following side effects have been reported and are typical with medicines similar to Jorveza (corticosteroids), and can therefore also occur with this medicine. The frequency of these events is currently not known:</p><p>increased risk of infection</p><p>Cushing s syndrome, which is associated with too much corticosteroid and causes roundness of the face, weight gain, high blood sugar, build-up of fluid in the tissues (e.g. swollen legs), reduced potassium level in the blood (hypokalaemia), irregular periods in women, unwanted body hair in women, impotence, stretch marks on the skin, acne.</p><p>slowed growth in children</p><p>mood changes, such as depression, irritability or euphoria</p><p>restlessness with increased physical activity, aggression</p><p>increased pressure in the brain, possibly with increased pressure in the eye (swelling of the optic disk) in adolescents</p><p>blurred vision</p><p>increased risk of blood clots, inflammation of the blood vessels (which can happen when the medicine is stopped after long-term use)</p><p>constipation, ulcers in the small intestine</p><p>inflammation of the pancreas, which causes severe pain in the belly and back</p><p>rash, red spots from bleeding in the skin, delayed wound healing, skin reactions such as contact dermatitis, bruising</p><p>muscle and joint pain, muscle weakness, muscle twitching</p><p>weakening of the bones (osteoporosis), bone damage due to poor circulation of blood (osteonecrosis)</p><p>general feeling of being ill.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store jorveza"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store jorveza"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not take this medicine after the expiry date which is stated on the carton and blister after EXP . The expiry date refers to the last day of that month.</p><p>Do not store above 25 C. Store in the original package in order to protect from light and moisture.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Jorveza contains</p><p>Jorveza 0.5 mg orodispersible tablet</p><ul><li><p>The active substance is budesonide. Each orodispersible tablet contains 0.5 mg of budesonide.</p></li><li><p>The other ingredients are disodium hydrogen citrate, docusate sodium, macrogol (6000), magnesium stearate, mannitol (E 421), anhydrous monosodium citrate, povidone (K25), sodium hydrogen carbonate and sucralose (see also section 2, Jorveza contains sodium ).</p></li></ul><p>Jorveza 1 mg orodispersible tablet</p><ul><li><p>The active substance is budesonide. Each orodispersible tablet contains 1 mg of budesonide.</p></li><li><p>The other ingredients are disodium hydrogen citrate, docusate sodium, macrogol (6000), magnesium stearate, mannitol (E 421), anhydrous monosodium citrate, povidone (K25), sodium hydrogen carbonate and sucralose (see also section 2, Jorveza contains sodium ).</p></li></ul><p>What Jorveza looks like and contents of the pack</p><p>Jorveza 0.5 mg orodispersible tablet</p><p>Jorveza 0.5 mg orodispersible tablets are white, round, biplane. They are debossed with 0.5 on one side. They come in blisters in packs with 20, 60, 90, 100 or 200 orodispersible tablets.</p><p>Jorveza 1 mg orodispersible tablet</p><p>Jorveza 1 mg orodispersible tablets are white, round, biplane. They come in blisters in packs with 20, 30, 60, 90, 100 or 200 orodispersible tablets.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer Dr. Falk Pharma GmbH Leinenweberstr. 5 79108 Freiburg Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Dr. Falk Pharma Benelux B.V. T l/Tel: +32-(0)16 40 40 <a href="mailto:info@drfalkpharma-benelux.eu">info@drfalkpharma-benelux.eu</a></p><p>Lietuva UAB Morf jus Tel: +370 5 <a href="mailto:2796biuras@morfejus.lt">2796biuras@morfejus.lt</a></p><p>Dr. Falk Pharma GmbH Te : +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Luxembourg/Luxemburg Dr. Falk Pharma Benelux B.V.<br/>T l/Tel: +32-(0)16 40 40 <a href="mailto:info@drfalkpharma-benelux.eu">info@drfalkpharma-benelux.eu</a></p><p>esk republika Ewopharma, spol. s r. o. Tel: +420 267 311 <a href="mailto:info@ewopharma.cz">info@ewopharma.cz</a> Magyarorsz g Ewopharma Hungary Kft. Tel.: +36 1 200 <a href="mailto:4info@ewopharma.hu">4info@ewopharma.hu</a><br/>Danmark Vifor Pharma Nordiska AB Tlf: +46 8 5580 <a href="mailto:6info.nordic@viforpharma.com">6info.nordic@viforpharma.com</a></p><p>Malta Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Deutschland Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Nederland Dr. Falk Pharma Benelux B.V. Tel: +31-(0)30 880 48 <a href="mailto:info@drfalkpharma-benelux.eu">info@drfalkpharma-benelux.eu</a></p><p>Eesti Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Norge Vifor Pharma Nordiska AB Tlf: +46 8 5580 <a href="mailto:6info.nordic@viforpharma.com">6info.nordic@viforpharma.com</a></p><p>GALENICA A.E T : +30 210 52 81 <a href="mailto:contact@galenica.gr">contact@galenica.gr</a></p><p>sterreich Dr. Falk Pharma sterreich GmbH Tel: +43 (1) 577 3516 0 <a href="mailto:office@drfalkpharma.at">office@drfalkpharma.at</a></p><p>Espa a Dr. Falk Pharma Espa a Tel: +34 91 372 95 <a href="mailto:drfalkpharma@drfalkpharma.es">drfalkpharma@drfalkpharma.es</a></p><p>Polska Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>France Dr. Falk Pharma SAS T l: +33(0)1 78 90 02 <a href="mailto:contact.fr@drfalkpharma.fr">contact.fr@drfalkpharma.fr</a></p><p>Portugal Dr. Falk Pharma Portugal, Sociedade Unipessoal Lda. Tel: +351 21 412 61 <a href="mailto:farmacovigilancia@drfalkpharma.pt">farmacovigilancia@drfalkpharma.pt</a></p><p>Hrvatska W rth d.o.o.<br/>Tel: +385 1 <a href="mailto:4650wurth@zg.t-com.hr">4650wurth@zg.t-com.hr</a></p><p>Ireland Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Rom nia Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Slovenija Ewopharma d.o.o. Tel: + 386 (0) 590 848 <a href="mailto:info@ewopharma.si">info@ewopharma.si</a></p><p>sland Dr. Falk Pharma GmbH S mi: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Slovensk republika Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Italia Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>Suomi/Finland Vifor Pharma Nordiska AB Puh/Tel: +46 8 5580 <a href="mailto:6info.nordic@viforpharma.com">6info.nordic@viforpharma.com</a></p><p>THESPIS PHARMACEUTICAL Ltd<br/>: +357 <a href="mailto:22677pharmacovigilance@thespispharma.com">22677pharmacovigilance@thespispharma.com</a> Sverige Vifor Pharma Nordiska AB Tel: +46 8 5580 <a href="mailto:6info.nordic@viforpharma.com">6info.nordic@viforpharma.com</a></p><p>Latvija UAB Morf jus Tel: +370 5 <a href="mailto:2796biuras@morfejus.lt">2796biuras@morfejus.lt</a> United Kingdom (Northern Ireland)<br/>Dr. Falk Pharma GmbH Tel: +49 761 1514 0 <a href="mailto:zentrale@drfalkpharma.de">zentrale@drfalkpharma.de</a></p><p>This leaflet was last revised in .</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp84f7be3473056391e7ee18f2463847a8"/>
<resource>
<MedicinalProductDefinition>
<id value="mp84f7be3473056391e7ee18f2463847a8"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp84f7be3473056391e7ee18f2463847a8"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp84f7be3473056391e7ee18f2463847a8</b></p><a name="mp84f7be3473056391e7ee18f2463847a8"> </a><a name="hcmp84f7be3473056391e7ee18f2463847a8"> </a><a name="mp84f7be3473056391e7ee18f2463847a8-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/17/1254/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Jorveza 0.5 mg orodispersible tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/17/1254/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Jorveza 0.5 mg orodispersible tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
